文献速递膀胱癌与上尿路尿路上皮癌

经皮穿刺活检在上尿路尿路上皮癌中的肿瘤学安全性与诊断效能:UPERCUT研究

Oncological Safety and Diagnostic Yield of Percutaneous Needle-core Biopsies in Upper Tract Urothelial Carcinoma: The UPERCUT Study.
PubMed 文献 · Eur Urol Oncol · 2025-04-21

这项回顾性多中心研究纳入53例2012至2022年间因疑似上尿路尿路上皮癌行经皮穿刺活检的患者,评估针道种植风险、诊断效能及肿瘤学结局。中位随访影像时间8.3个月,针道种植发生1例(1.9%),活检诊断率94%,肿瘤分期和分级组织学一致率分别为78%和100%,并发症发生率14.8%。结论认为经皮活检对高级别浸润性上尿路尿路上皮癌是有用的诊断工具,针道种植风险低。

要点

  • 经皮穿刺活检后针道种植发生率为1.9%(1例),风险较低。
  • 活检诊断率94%,肿瘤分级组织学一致率100%,分期一致率78%。
  • 并发症发生率14.8%,其中需内镜处理的梗阻性肾盂肾炎占3.7%。

核心结论

  • 经皮穿刺活检是高级别浸润性上尿路尿路上皮癌的有用诊断工具,针道种植风险低。
  • 活检提供关键组织学确认,有助于未来新辅助系统治疗研究。

研究设计与样本

  • 回顾性多中心研究,纳入2012至2022年间53例因上尿路尿路上皮癌行经皮穿刺活检的患者。
  • 主要终点为经中心化影像复查评估的活检针道肿瘤复发,次要终点包括活检诊断率、与肾输尿管切除术后最终病理的分期分级一致率、并发症率及总体肿瘤学结局。

主要发现

  • 队列中男性占60%,平均年龄69岁,诊断时32%存在转移性疾病。
  • 中位随访影像时间8.3个月,针道种植发生1例(1.9%),发生于术后5个月。
  • 活检诊断率94%,肿瘤分期组织学一致率78%,分级一致率100%。
  • 并发症发生率14.8%,包括2例(3.7%)需内镜处理的梗阻性肾盂肾炎。

临床怎么用

  • 对于诊断不确定的上尿路尿路上皮癌(如与肾细胞癌或其他疾病鉴别、远处转移或内镜活检失败),经皮穿刺活检可提供组织学确认。
  • 活检结果可用于指导治疗决策,并为新辅助系统治疗研究提供依据。

局限性

  • 回顾性多中心设计,样本量53例,中位随访影像时间仅8.3个月。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: A percutaneous biopsy of suspected upper tract urothelial carcinoma (UTUC) is considered contraindicated due to potential safety concerns. This study evaluated the risk of tumor seeding along the needle track following a percutaneous needle-core biopsy for UTUC, along with diagnostic yield and oncological outcomes. METHODS: We conducted a retrospective multicenter study involving 53 patients who underwent a percutaneous biopsy for upper urinary tract urothelial carcinoma between 2012 and 2022. The primary endpoint was tumor recurrence along the biopsy needle track, assessed through a centralized review of follow-up cross-sectional imaging. The secondary endpoints included biopsy yield, histological concordance in tumor stage and grade compared with final histology in cases of nephroureterectomy, complication rates, and overall oncological outcomes. KEY FINDINGS AND LIMITATIONS: The cohort consisted of 60% male patients with a mean age of 69 yr. At diagnosis, 32% had metastatic disease. A biopsy was performed due to diagnostic uncertainty regarding renal cell carcinoma or other diseases, distant metastases, or failed endoscopic biopsy. The median follow-up imaging time was 8.3 mo. Tumor track seeding occurred in one case (1.9%) 5 mo after the procedure. Biopsy yield was 94%, with histological concordance rates of 78% for tumor stage and 100% for grade. Complications occurred in 14.8% of cases, including two (3.7%) cases of obstructive pyelonephritis requiring endoscopic management. CONCLUSIONS AND CLINICAL IMPLICATIONS: A percutaneous biopsy is a useful diagnostic tool for high-grade invasive upper urinary tract urothelial carcinoma, with a low risk of tumor track seeding. It provides critical histological confirmation, facilitating future research on neoadjuvant systemic therapies.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Prost D, Pachev A, Kerviler E, et al. Oncological Safety and Diagnostic Yield of Percutaneous Needle-core Biopsies in Upper Tract Urothelial Carcinoma: The UPERCUT Study. Eur Urol Oncol. 2025. PMID: 40263080. doi:10.1016/j.euo.2025.03.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。